View this article online: https://www.claimsjournal.com/news/southcentral/2010/04/08/108859.htm
Attorney General Buddy Caldwell announced that Louisiana has settled its lawsuit against pharmaceutical company Eli Lilly concerning its off-label marketing of the antipsychotic drug Zyprexa. Louisiana will receive $20 million as part of the settlement.
The suit, filed under the state’s Louisiana Unfair and Deceptive Trade Practices Act, alleged that Eli Lilly engaged in unfair and deceptive practices when it promoted the off-label marketing of Zyprexa. Zyprexa is an antipsychotic medication used to treat psychological disorders such as schizophrenia and bipolar disorders in adults only.
The suit alleged that despite the fact that Zyprexa had not been tested or approved by the Food and Drug Administration (FDA) for pediatric use, Eli Lilly marketed the drug for use with children.
The suit further alleged that Zyprexa was not approved for off-label usage for treatment of illnesses such as depression, anxiety, attention deficit sleep disorders, anger management, or mood stabilizers. As a result of the offlabel marketing of Zyprexa, the state suffered harm and incurred medical expenses to treat the health affects of those suffering from Zyprexa related illnesses such as diabetes and seizures.
The following are included in the terms of the settlement:
Funds from the settlement will go to: the Louisiana General Fund ($16,947,504.96); Medicaid restitution ($1,526,247.52); and additional Medicaid recovery ($1,526,247.52).
The Eli Lilly case was handled by private counsel appointed by the attorney general. Eli Lilly will pay fees to private counsel for the state in addition to the settlement with the state. No portion of the state’s recovery was utilized in the payment of attorneys’ fees.
Source: Louisiana Attorney General’s Office